Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Vaccine Immunity in CAR-T Cell Therapy Recipients
Interventions
BIOLOGICAL

Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles

"First immunization course (6±1 months post CAR-T treatment):~1. Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b (as by the Swiss guidelines\[FOPH\] all of these are administered in one combined vaccine; INFANRIX DTPa-IPV+Hib Inj Susp®; GlaxoSmithKline)~2. Hepatitis B (Engerix B®, GlaxoSmithKline)~3. 13-valent Streptococcus pneumonia vaccine (Prevenar-13®; Pfizer)~4. Herpes zoster vaccine in patients with documented prior seropositivity or known varicella-infection in patient history (as by The Swiss guidelines; Shingrix®; GlaxoSmithKline)~5. Tick-borne encephalitis (as by The Swiss guidelines; FSME Immun CC®; Pfizer or Encepur N®, BavarianNordic; these vaccines can be used interchangeably)~Second immunization course (12±1 months post CAR-T treatment):~1. Mumps, measles, rubella (Priorix®, GlaxoSmithKline)~2. Varicella zoster vaccine (as by guidelines; Varilrix®, GlaxoSmithKline) If seronegative/patient history negative"

Trial Locations (1)

3010

RECRUITING

University Hospital Bern, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER